消息面上，先瑞达医疗发布中期业绩，上半年收入3.51亿元人民币，同比增加20.1%；期内溢利8857.7 万元，同比增加121.7%。此外，公司收到中国国家药品监督管理局对外周可控机械解脱带纤维毛弹簧 圈的注册批准。该产品用于外周血管的动脉瘤、动静脉畸形和动静脉瘘的填塞。公司将适时在中国开展 营销活动。 公开资料显示，2022年12月，先瑞达医疗发布公告称，波士顿科学向公司先瑞达发起要约收购，以每股 20港元的价格交易先瑞达不超过65%股份的多数股权，预计交易金额约为5.23亿美元，完成交易后，波 科成为先瑞达医疗的控股公司。2023年7月，双方签订了合作框架协议和服务框架协议，双方将在产品 全球商业化、产品制造服务和产品研发等领域开展合作。 先瑞达医疗-B(06669)绩后涨超13%，截至发稿，涨9.81%，报12.42港元，成交额1101.11万港元。 ...

Core Viewpoint - Xianruida Medical-B (06669) experienced a significant stock price increase of over 13% following the release of its interim results, indicating positive market sentiment towards the company's performance and future prospects [1] Financial Performance - The company reported a revenue of 351 million RMB for the first half of the year, representing a year-on-year increase of 20.1% [1] - Net profit for the same period was 88.577 million RMB, showing a substantial year-on-year growth of 121.7% [1] Regulatory Approval - Xianruida Medical received registration approval from the National Medical Products Administration of China for its peripheral controllable mechanical release fiber spring ring, which is intended for use in treating peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas [1] - The company plans to initiate marketing activities in China for this product in a timely manner [1] Strategic Developments - In December 2022, Boston Scientific initiated a takeover bid for Xianruida Medical, offering 20 HKD per share for up to 65% of the company's majority stake, with an estimated transaction value of approximately 523 million USD [1] - In July 2023, both parties signed a cooperation framework agreement and service framework agreement to collaborate on global commercialization, manufacturing services, and product development [1]

Core Viewpoint - The company, Xianruida Medical-B (06669), has received approval from the National Medical Products Administration of China for its controllable mechanical embolization spring coil, which is designed for peripheral vascular applications [1] Product Details - The product is intended for the embolization of peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas [1] - It features a controllable release mechanism that ensures a stable and precise deployment of the spring coil, enhancing operational control and safety [1] - The product is available in both 2D and 3D structures, allowing for broad adaptability to clinical needs [1] Marketing Plans - The company plans to initiate marketing activities in China at an appropriate time following the product approval [1]

Core Viewpoint - The company, Xianruida Medical-B (06669), has received approval from the National Medical Products Administration of China for its controllable mechanical detachable fiber spring coil, which is designed for embolization of peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas [1] Product Details - The product features a controllable release mechanism that ensures a stable and precise deployment of the spring coil, enhancing operational controllability and safety [1] - It offers both 2D and 3D structural options, allowing for broad adaptability to clinical needs [1] Market Strategy - The company plans to initiate marketing activities in China at an appropriate time following the product approval [1]

Core Viewpoint - The company, Xianruida Medical-B (06669.HK), has received registration approval from the National Medical Products Administration of China for its controllable mechanical embolization spring coil, which is designed for peripheral vascular applications [1] Group 1: Product Details - The product is intended for the embolization of peripheral vascular aneurysms, arteriovenous malformations, and arteriovenous fistulas [1] - It features a controllable release mechanism that ensures a stable and precise deployment of the spring coil, enhancing operational control and safety [1] - The product is available in both 2D and 3D structures, allowing for broad adaptability to clinical needs [1] Group 2: Market Strategy - The company plans to initiate marketing activities in China at an appropriate time following the approval [1]